FDA grants expanded approval for Bristol Myers Squibb anemia therapy - NJBIZ

“The approval of Reblozyl in the first-line treatment of anemia for patients with lower-risk MDS represents a crucial step in making transfusion independence possible for more patients," said Tracey Iraca, executive director of the MDS Foundation.

NJBIZ Conversations: Craig Dubitsky - NJBIZ

U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy

Bristol-Myers Squibb Baraclude Patient Assistance - Needy Meds

U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma

FDA Approves Expansion for BMS' Reblozyl as First-Line Anemia Treatment

Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions

Lee & Associates New Jersey relocates to Elmwood Park - NJBIZ

Four NJ entities to lead new pediatric payment model with $15.8M CMS award - NJBIZ

Bristol Myers Squibb - Recent News & Activity

New COVID-19 relief package would allow cannabiz banking and insurance - NJBIZ

TechLaunch names winners at virtual pitch event - NJBIZ

Carlyle buying broadcasting, streaming firm LiveU for $400M - NJBIZ